You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydrocodone
Accession NumberDB00956  (APRD00591, DB09475)
TypeSmall Molecule
GroupsApproved, Illicit
Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. [PubChem]

Structure
Thumb
Synonyms
(-)-Dihydrocodeinone
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
Dihydrocodeinone
Hidrocodona
Hydrocodon
Hydrocodone
Hydrocodonum
Hydrocone
Hydroconum
Idrocodone
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hycodan Syrupsyrup1 mgoralBristol Myers Squibb Canada1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hycodan Tabletstablet5 mgoralBristol Myers Squibb Canada1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hysingla ERtablet, extended release100 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release40 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release30 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release20 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release80 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release120 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hysingla ERtablet, extended release60 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
PMS-hydrocodonesyrup1 mgoralPharmascience Inc2009-03-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Robidone 1mg/ml Syrsyrup1 mgoralWyeth Ayerst Canada Inc.1993-12-312001-11-06Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Robidone Syr 1mg/mlsyrup1 mgoralAyerst Laboratories1991-12-311997-08-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Zohydrocapsule, extended release10 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release15 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release10 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release50 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release40 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release50 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release30 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release40 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release20 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release30 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release15 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydrocapsule, extended release20 mg/1oralZogenix, Inc.2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release10 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release50 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release40 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release30 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release20 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Zohydro ERcapsule, extended release15 mg/1oralPernix Therapeutics2013-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
CodofenPaladin Labs Inc
Coristine-DH LiqTechnilab Pharma Inc.
Dimetane Expectorant DcPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetane Expectorant-DC SyrWhitehall Robins Inc.
Direct RxDIRECT RX
FlowtussMission Pharmacal Company
HycetG&W Laboratories, Inc.
HycofenixMission Pharmacal Company
Hydrocodone AcetaminophenRed Pharm Drug Inc.
Hydrocodone Bit/apapMedsource Pharmaceuticals
Hydrocodone Bitartate and AcetaminophenActavis Pharma, Inc.
Hydrocodone BitartrateDIRECT RX
Hydrocodone Bitartrate and AcetaminophenPharmaceutical Associates, Inc.
Hydrocodone Bitartrate and Acetaminophen TabletsRed Pharm Drug Inc.
Hydrocodone Bitartrate and Chlorpheniramine Maleate SolutionTris Pharma Inc
Hydrocodone Bitartrate and Homatropine MethylbromidePharmaceutical Associates, Inc.
Hydrocodone Bitartrate and IbuprofenTeva Pharmaceuticals USA Inc
Hydrocodone Bitartrate and Pseudoephedrine Hydrochloride SolutionTris Pharma Inc
Hydrocodone Bitartrate With AcetaminophenApotheca Inc.
Hydrocodone Bitartrate, Chlorpheniramine Maleate and Pseudoephedrine HydrochloridePaddock Laboratories, LLC
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine HClCypress Pharmaceutical, Inc.
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine Hydrochloride Oral SolutionTris Pharma Inc
Hydrocodone Bitatrate and AcetaminophenActavis Pharma, Inc.
Hydrocodone Polistirex and Chlorpheniramine PolisitrexAtlantic Biologicals Corps
Hydrocodone Polistirex and Chlorpheniramine PolistirexPhysicians Total Care, Inc.
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-releaseAristos Phamaceuticals, Inc.
Hydrocodone Polistirex and Chlorpheniramine Polistirex PennkineticAtlantic Biologicals Corps
Hydrocodone/apapPharm Pak, Inc.
HydrometActavis Mid Atlantic LLC
IbucodonePaladin Labs Inc
IbudonePoly Pharmaceuticals
LorcetCardinal Health
Lorcet 10/650Rx Pak Division Of Mc Kesson Corporation
Lorcet HdMidlothian Laboratories
Lorcet PlusCardinal Health
LortabECR Pharmaceuticals
Lortab 10/325UCB, Inc.
Lortab 5/325UCB, Inc.
Lortab 7.5/325UCB, Inc.
MaxidoneWatson Pharma, Inc.
NorcoActavis Pharma, Inc.
Novahistex DhSanofi Aventis Canada Inc
Novahistex Dh ExpectorantAventis Pharma Inc
Novahistine DhSanofi Aventis Canada Inc
ObredonNovotec Pharma Llc
Ratio-coristex-DHRatiopharm Inc Division Of Teva Canada Limited
ReprexainStat Rx USA
ReziraHawthorn Pharmaceuticals, Inc.
Theracodophen-325Physician Therapeutics Llc
Theracodophen-650Physician Therapeutics Llc
Theracodophen-750Physician Therapeutics Llc
Theracodophen-low-90Physician Therapeutics Llc
TussicapsECR Pharmaceuticals
TussigonPfizer Laboratories Div Pfizer Inc
Tussionex PennkineticUnither Manufacturing, LLC
Vasofrinic DhLaboratoires Trianon Inc
VicodinAbb Vie Inc.
Vicodin EsAbb Vie Inc.
Vicodin HpAbb Vie Inc.
VicoprofenAbb Vie Inc.
VituzHawthorn Pharmaceuticals, Inc.
XodolRebel Distributors Corp.
Xylon 10Sircle Laboratories, Llc
ZamicetPharmaceutical Associates, Inc.
ZutriproHawthorn Pharmaceuticals, Inc.
ZydoneSTAT Rx USA LLC
Salts
Name/CASStructureProperties
Hydrocodone bitartrate
ThumbNot applicableDBSALT001233
Hydrocodone polistirex
ThumbNot applicableDBSALT001602
Categories
CAS number125-29-1
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
InChI KeyInChIKey=LLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.
PharmacodynamicsHydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.
Mechanism of actionHydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingAs most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
Metabolism

Hepatic and also in intestinal mucosa.

SubstrateEnzymesProduct
Hydrocodone
hydromorphoneDetails
Hydrocodone
norhydrocodoneDetails
Route of eliminationNot Available
Half life1.25-3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydrocodone Action PathwayDrug actionSMP00411
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 inhibitorNon-inhibitor0.9412
CYP450 2D6 inhibitorInhibitor0.6629
CYP450 2C19 inhibitorNon-inhibitor0.8402
CYP450 3A4 inhibitorNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Syruporal1 mg
Tabletoral5 mg
Liquidoral
Solutionoral
Suspension, extended releaseoral
Suspensionoral
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral120 mg/1
Tablet, extended releaseoral20 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral40 mg/1
Tablet, extended releaseoral60 mg/1
Tablet, extended releaseoral80 mg/1
Syruporal
Kit
Capsule, extended releaseoral
Tabletoral
Tablet, coatedoral
Tablet, film coatedoral
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral15 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral50 mg/1
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.3 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-ozt1000000-3ba3e105098639cd6091View in MoNA
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, “Morphinone reductase for the preparation of hydromorphone and hydrocodone.” U.S. Patent US5571685, issued November, 1990.

US5571685
General ReferencesNot Available
External Links
ATC CodesR05DA03
AHFS Codes
  • 48:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.8 KB)
Interactions
Drug Interactions
Drug
AcetazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Acetazolamide.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AlvimopanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amiloride.
AmiodaroneThe serum concentration of Hydrocodone can be increased when it is combined with Amiodarone.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AmlodipineThe serum concentration of Hydrocodone can be increased when it is combined with Amlodipine.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydrocodone which could result in a higher serum level.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AmphetamineAmphetamine may increase the analgesic activities of Hydrocodone.
AprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ArmodafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Armodafinil.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
AtazanavirThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.
AtorvastatinThe serum concentration of Hydrocodone can be increased when it is combined with Atorvastatin.
AzelastineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.
BexaroteneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Hydrocodone can be increased when it is combined with Bicalutamide.
BoceprevirThe serum concentration of Hydrocodone can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BumetanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.
BupropionThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Bupropion resulting in a loss in efficacy.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ButorphanolButorphanol may decrease the analgesic activities of Hydrocodone.
CalcitriolThe serum concentration of Hydrocodone can be decreased when it is combined with Calcitriol.
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CathinoneCathinone may increase the analgesic activities of Hydrocodone.
CeritinibThe serum concentration of Hydrocodone can be increased when it is combined with Ceritinib.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CilostazolThe serum concentration of Hydrocodone can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Hydrocodone can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.
CiprofloxacinThe serum concentration of Hydrocodone can be increased when it is combined with Ciprofloxacin.
ClarithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ClotrimazoleThe serum concentration of Hydrocodone can be increased when it is combined with Clotrimazole.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CobicistatThe serum concentration of Hydrocodone can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cocaine resulting in a loss in efficacy.
ConivaptanThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Hydrocodone can be increased when it is combined with Crizotinib.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
CyclosporineThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclothiazide.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DabrafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.
DanazolThe serum concentration of Hydrocodone can be increased when it is combined with Danazol.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DarunavirThe serum concentration of Hydrocodone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Hydrocodone can be increased when it is combined with Delavirdine.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DesmopressinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.
DesvenlafaxineThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.
Dexchlorpheniramine maleateDexchlorpheniramine maleate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DicloxacillinThe serum concentration of Hydrocodone can be decreased when it is combined with Dicloxacillin.
DiltiazemThe serum concentration of Hydrocodone can be increased when it is combined with Diltiazem.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DronedaroneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EluxadolineHydrocodone may increase the activities of Eluxadoline.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EnzalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.
ErythromycinThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EstradiolThe serum concentration of Hydrocodone can be decreased when it is combined with Estradiol.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Ethacrynic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethacrynic acid.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethoxzolamide.
EtravirineThe serum concentration of Hydrocodone can be decreased when it is combined with Etravirine.
ExemestaneThe serum concentration of Hydrocodone can be decreased when it is combined with Exemestane.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FluconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Fluconazole.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FluoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FluvoxamineThe serum concentration of Hydrocodone can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Hydrocodone can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Fosaprepitant.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
FurosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.
Fusidic AcidThe serum concentration of Hydrocodone can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Glycerol PhenylbutyrateThe serum concentration of Hydrocodone can be increased when it is combined with Glycerol Phenylbutyrate.
GriseofulvinThe serum concentration of Hydrocodone can be decreased when it is combined with Griseofulvin.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
IdelalisibThe serum concentration of Hydrocodone can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ImatinibThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
IndapamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.
IndinavirThe serum concentration of Hydrocodone can be increased when it is combined with Indinavir.
IsavuconazoniumThe serum concentration of Hydrocodone can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
IsoniazidThe serum concentration of Hydrocodone can be increased when it is combined with Isoniazid.
ItraconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Hydrocodone can be increased when it is combined with Ivacaftor.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
KetoconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Ketoconazole.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LapatinibThe serum concentration of Hydrocodone can be increased when it is combined with Lapatinib.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Hydrocodone.
LomitapideThe serum concentration of Hydrocodone can be increased when it is combined with Lomitapide.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
LuliconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Luliconazole.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Medroxyprogesterone AcetateThe serum concentration of Hydrocodone can be decreased when it is combined with Medroxyprogesterone Acetate.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MethotrimeprazineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MetolazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.
MetyraponeThe serum concentration of Hydrocodone can be decreased when it is combined with Metyrapone.
MetyrosineHydrocodone may increase the sedative activities of Metyrosine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MifepristoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MitotaneThe serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.
ModafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Modafinil.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
NafcillinThe serum concentration of Hydrocodone can be decreased when it is combined with Nafcillin.
NaltrexoneThe therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.
NefazodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Hydrocodone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Hydrocodone can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Hydrocodone can be increased when it is combined with Nicardipine.
NilotinibThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
OritavancinThe serum concentration of Hydrocodone can be decreased when it is combined with Oritavancin.
OrphenadrineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
OxcarbazepineThe serum concentration of Hydrocodone can be decreased when it is combined with Oxcarbazepine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PaclitaxelThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ParaldehydeHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.
PazopanibThe serum concentration of Hydrocodone can be increased when it is combined with Pazopanib.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PhenytoinThe serum concentration of Hydrocodone can be decreased when it is combined with Phenytoin.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PioglitazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pioglitazone.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PosaconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.
PramipexoleHydrocodone may increase the sedative activities of Pramipexole.
PrednisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Prednisone.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Hydrocodone.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
QuinidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Quinidine resulting in a loss in efficacy.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
RamosetronHydrocodone may increase the activities of Ramosetron.
RanolazineThe serum concentration of Hydrocodone can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
RifabutinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Hydrocodone can be decreased when it is combined with Rifapentine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
RitonavirThe serum concentration of Hydrocodone can be increased when it is combined with Ritonavir.
RopiniroleHydrocodone may increase the sedative activities of Ropinirole.
RotigotineHydrocodone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydrocodone.
SaquinavirThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Scopolamine butylbromideScopolamine butylbromide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydrocodone.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
SiltuximabThe serum concentration of Hydrocodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Hydrocodone can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
SpironolactoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.
St. John's WortThe serum concentration of Hydrocodone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Hydrocodone can be increased when it is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydrocodone.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
SuvorexantHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Hydrocodone.
TelaprevirThe serum concentration of Hydrocodone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Telithromycin.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TerbinafineThe serum concentration of Hydrocodone can be decreased when it is combined with Terbinafine.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ThalidomideHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TicagrelorThe serum concentration of Hydrocodone can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Hydrocodone can be increased when it is combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ticrynafen.
TipranavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TocilizumabThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TorasemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TrametinibThe serum concentration of Hydrocodone can be decreased when it is combined with Trametinib.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.
TriamtereneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
VemurafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Vemurafenib.
VerapamilThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
VoriconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Voriconazole.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

Targets

1. Mu-type opioid receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Mu-type opioid receptor P35372 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. Pubmed
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. Pubmed
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. Pubmed
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. Pubmed
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Jul 28. Pubmed
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. Epub 2008 Jul 7. Pubmed

2. Delta-type opioid receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Delta-type opioid receptor P41143 Details

References:

  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. Pubmed
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2015 13:43